Note B - Going Concern and Liquidity	12 Months Ended
Dec. 31, 2024
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE B--GOING CONCERN AND LIQUIDITY Our financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company on a going concern basis. The going concern basis assumes that assets are realized, and liabilities are extinguished in the ordinary course of business at amounts disclosed in the financial statements. The Company has incurred total losses since inception of $128.1 million. The Company’s operating losses were $6.8 million and $7.1 million, for the years ended December 31, 2024, and 2023, respectively . On December 31, 2024, Milestone Scientific had cash and cash equivalents of approximately $3.3 million and working capital of approximately $5.5 million. For the years ended December 31, 2024 and 2023, we had cash flows used in operating activities of approximately $2.9 million and $5.3 million, respectively. These conditions raise substantial doubt about the company ability to continue as a going concern. Management has developed and is implementing plans to increase revenues and decrease professional and consulting fees over the next twelve months. The Company has also decided to delay all research and development on the Single Tooth Anesthesia System next generation instrument. The Company believes that the existing cash and cash equivalents along with management plans, and the $800,000 in related party note financing received in April 2025 (See Note P) will be sufficient to enable the Company to fund operations for the twelve months from the issuance of these financial statements and alleviates substantial doubt about the Company’s ability to continue as a going concern. The Company is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Company’s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever.

Note B - Going Concern and Liquidity

12 Months Ended

Dec. 31, 2024

Substantial Doubt about Going Concern [Text Block]

NOTE B--GOING CONCERN AND LIQUIDITY

Our financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company on a going concern basis. The going concern basis assumes that assets are realized, and liabilities are extinguished in the ordinary course of business at amounts disclosed in the financial statements.

The Company has incurred total losses since inception of $128.1 million. The Company’s operating losses were $6.8 million and $7.1 million, for the years ended December 31, 2024, and 2023, respectively . On December 31, 2024, Milestone Scientific had cash and cash equivalents of approximately $3.3 million and working capital of approximately $5.5 million. For the years ended December 31, 2024 and 2023, we had cash flows used in operating activities of approximately $2.9 million and $5.3 million, respectively. These conditions raise substantial doubt about the company ability to continue as a going concern.

Management has developed and is implementing plans to increase revenues and decrease professional and consulting fees over the next twelve months. The Company has also decided to delay all research and development on the Single Tooth Anesthesia System next generation instrument. The Company believes that the existing cash and cash equivalents along with management plans, and the $800,000 in related party note financing received in April 2025 (See Note P) will be sufficient to enable the Company to fund operations for the twelve months from the issuance of these financial statements and alleviates substantial doubt about the Company’s ability to continue as a going concern.

The Company is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Company’s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever.